Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chevron

Dell Technologies

The rising market in 2023 has not lifted all boats. Some stocks look extremely cheap right now.

The 3 Best Cheap Stocks to Buy in December

Brookfield Renewable Partners

Realty Income Corp

Verizon

Higher interest rates have pushed up the yields on many dividend-paying stocks. Realty Income, Brookfield Renewable, AbbVie, and Verizon currently offer yields above 4%.

4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December

AbbVie announced two major acquisitions in seven days. Buying ImmunoGen and Cerevel Therapeutics should make AbbVie more competitive in oncology and neuroscience.

AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?

Genmab - ADR

-  Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congress -  Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma NORTH CHICAGO, Ill. , Dec. 9, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with two or more prior therapies experienced strong and durable responses with high overall response (ORR) and complete response (CR) rates when treated with epcoritamab (DuoBody® CD3xCD20), an investigational, subcutaneously administered T-cell engaging bispecific antibody.

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR) rate of 63 percent and minimal residual disease (MRD) negativity rate of 67 percent in patients with relapsed/refractory (R/R) folli.

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

Apple

Broadcom

Blackrock Inc

Home Depot

Johnson & Johnson

JPMorgan Chase & Co

Coca-Cola

Mastercard

Merck

Microsoft

PepsiCo

Procter & Gamble

Schwab US Dividend Equity ETF

iShares 20+ Year Treasury Bond ETF

Texas Instruments

UnitedHealth Group

Visa

Vanguard Dividend Appreciation ETF

Vanguard High Dividend Yield ETF

Walmart

Exxon Mobil

The economic cycles have always been with us. But the frequency of boom and bust cycles has certainly increased in the last couple of decades. If the volatility of the stock market keeps you awake at night, this article is for you. The market has been rallying for some time now. Will the bull rally continue in 2024? This article addresses some of the questions and recommends how to invest fresh capital.

How To Invest $100,000 Today In A Sleep Well Portfolio

Kenvue

AbbVie is proving its resilience with how it's navigating the loss of patent exclusivity for Humira. Kenvue markets iconic brands that should continue dominating the market for years to come.

3 Dividend Stocks You Can Safely Hold for Decades

Medical Properties Trust

AbbVie offers an above-average dividend yield and its payout has risen sharply in recent years. Medical Properties Trust slashed its dividend in half this year and it still offers an enormous 12.6% yield at recent prices.

Better Dividend Stock: AbbVie vs. Medical Properties Trust

Cerevel Therapeutics Holdings Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cerevel Therapeutics (NasdaqCM: CERE) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Cerevel will receive $45.00 in cash for each share of Cerevel that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe.

CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE

Cisco Systems

AbbVie, Exxon Mobil, and Cisco are three stocks that offer above-average yields. These stocks have all been increasing their dividend payments for years.

3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows

The drugmaker is doubling down on cancer and neurology as it seeks to replace falling revenue from its top sellers.

$19 Billion in a Week: AbbVie Makes Two Big Bets

On Dec. 6, AbbVie agreed to acquire Cerevel Therapeutics for $8.7 billion. On Nov. 30, AbbVie announced a $10.1 billion acquisition of ImmunoGen.

AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?

Vertex Pharmaceuticals

Healthcare stocks are a great way for investors to achieve long-term wealth creation. The healthcare sector is essential to solving some of the world's most pressing issues from heart disease, Alzheimer's, and cancer.

Healthcare Gems: 3 Essential Long-Term Stock Picks

Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.

AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio

AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said.

AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) jumped some 12% today after AbbVie Inc (NYSE: ABBV) said it will buy the drug company that focuses primarily on neurological disorders. AbbVie seems to be on a buying spree AbbVie is willing to spend about $8.

Cramer reacts to AbbVie buying Cerevel Therapeutics

AbbVie Inc announced late Wednesday an agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $45 per share in cash, or a total equity value of approximately $8.7 billion.  Cerevel's portfolio includes drugs such as Emraclidine, an experimental treatment for both schizophrenia and Alzheimer's disease psychosis, which is currently in a Phase I study in elderly healthy volunteers.

AbbVie to acquire drugmaker Cerevel Therapeutics for $8.7B

ImmunoGen

U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals to support its growth.

Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout

AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.

AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B

AbbVie said late Wednesday it will buy Cerevel Therapeutics for $45 a share, or about $8.7 billion, in an all-cash deal.

AbbVie Does It Again With Fresh Pharma Acquisition

Medtronic

Pfizer

These companies all have solid histories of dividend increases and are making future dividend payments a priority. You can likely count on them to grow your passive income from year to year.

Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.

Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer in a multi-billion dollar deal.

Cerevel options trading surge before AbbVie deal news raises eyebrows

AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Humira faces a raft of new competition.

AbbVie to buy drug developer Cerevel for $8.7 billion

AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's “robust” neuroscience pipeline adds medications that may transform standards of care in psychiatric and neurological illnesses.

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion AbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CT NORTH CHICAGO, Ill.

News for AbbVie Stock (ABBV)